Earnings calls

CORONA Remedies Limited concall ledger

Every earnings call for CORONA — management tone, guidance, KPIs and promise tracking, quarter by quarter.

CORONA · 3 transcripts · Healthcare · latest Q4 FY26

CORONA Remedies Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.

Q4 FY26Published 12 May 2026Call held 12 May 2026

CORONA Q4 FY26 Earnings Call Transcript & Analysis

FY26 Revenue₹1,403 cr+17% YoYFY26 EBITDA₹293 cr+22% YoYFY26 EBITDA Margin20.9%FY26 Adjusted PAT₹199 cr+33% YoYFY26 ROCE41%

FY26 Revenue ₹1,403 cr (+17% YoY); FY26 EBITDA ₹293 cr (+22% YoY); FY26 EBITDA Margin 20.9%. FY26 Revenue of INR 1,403 crores, up 17.3% YoY.

Read full transcript & analysis

Q3 FY26Published 03 Feb 2026Call held 03 Feb 2026

CORONA Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹342 cr+15% YoYEBITDA₹83 cr+20% YoYEBITDA Margin24.3%

Revenue (Q3 FY26) ₹342 cr (+15% YoY); EBITDA (Q3 FY26) ₹83 cr (+20% YoY); EBITDA Margin (Q3 FY26) 24.3%. Q3 FY26 Revenue grew 15% YoY to ₹342 crores.

Read full transcript & analysis

Q2 FY26Published 05 Jan 2026Call held 05 Jan 2026

CORONA Q2 FY26 Earnings Call Transcript & Analysis

Q2 FY26 Revenue₹361.1 cr+15% YoYQ2 FY26 EBITDA₹78.5 cr+17% YoYQ2 FY26 EBITDA Margin21.7%Q2 FY26 PAT₹52.3 cr+22% YoYH1 FY26 Revenue₹707.7 cr+17% YoY

Q2 FY26 Revenue ₹361 cr (+15% YoY); Q2 FY26 EBITDA ₹78 cr (+17% YoY); Q2 FY26 EBITDA Margin 21.7%. Q2 FY26 Revenue grew 15.1% YoY to ₹361.1 crores.

Read full transcript & analysis